The Food and Drug Administration has approved Rasonque, the brand name for daraxonrasib, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic treatment or are not candidates for multiagent systemic therapy. The Aug. 26 decision gives the eligible population an approved once-daily oral targeted medicine in a cancer that has had few effective options after initial treatment.
The approval rests on a 500-patient randomized phase 3 trial in which median overall survival was 13.2 months for people assigned to daraxonrasib, compared with 6.7 months for those assigned to standard chemotherapy, according to the FDA announcement. Random assignment means the comparison can support a treatment effect in the studied group, rather than merely showing an association. But the result is not a forecast of how long any one patient will live, and it does not establish that the drug is suitable for everyone with pancreatic cancer.
What the approval covers
Rasonque is approved specifically for adults with metastatic pancreatic adenocarcinoma, the most common type of pancreatic cancer, after at least one systemic therapy or when multiagent systemic treatment is not appropriate. The FDA approved the drug for Revolution Medicines Inc. Its label does not make it a replacement for initial treatment for all patients, nor does the decision apply to earlier-stage pancreatic cancer.
Daraxonrasib is a RAS inhibitor, designed to interfere with altered RAS proteins that can drive tumor-cell growth. The FDA describes it as targeting multiple forms of RAS, a distinction from medicines aimed at one particular mutation. The agency called it the first approved therapy of its class for metastatic pancreatic cancer. That broad RAS-targeting approach is relevant because RAS alterations are common in pancreatic adenocarcinoma, but the approved indication is defined by the clinical setting, not in the FDA announcement by a single named RAS or KRAS mutation.
The pivotal RASolute 302 study was randomized, open-label and conducted at multiple centers among adults with previously treated metastatic disease. An open-label trial means patients and clinicians knew which treatment had been assigned. That design is less likely to alter a hard endpoint such as death than subjective symptom reporting, but it can still affect care decisions and some assessments during a trial.
How large was the trial benefit?
Beyond the overall-survival result reported by the FDA, a Dana-Farber account of the trial reported median progression-free survival of 7.2 months with daraxonrasib and 3.6 months with chemotherapy. It also reported objective response rates of 31.6% and 11.2%, respectively. Progression-free survival measures time before documented tumor growth or death; response rates describe the share of patients whose tumors shrink by a specified amount. Neither measurement means every patient benefited.
Median overall survival marks the point at which half the participants in a treatment group had died and half were still alive. The 6.5-month difference between the reported medians is substantial in a population with metastatic pancreatic cancer, but medians are group summaries, not individual prognoses. Responses and survival can vary with a patient’s overall health, tumor biology, prior therapies and complications of advanced disease.
The FDA’s description of the trial provides the core outcome but not the full study report, including detailed subgroup estimates, duration of follow-up and complete safety tables. Dana-Farber and the Pancreatic Cancer Action Network have said detailed RASolute 302 findings were presented at the American Society of Clinical Oncology meeting and published in the New England Journal of Medicine. The PanCAN overview, published before the FDA action, also described the results in the context of treatment after prior chemotherapy.
Side effects and access changed before approval
Targeted does not mean free of difficult side effects. The FDA lists rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite and hemorrhage among Rasonque’s most common adverse effects. Whether treatment is a reasonable option for a particular person will depend on clinical circumstances, prior treatments and the ability to monitor and manage toxicity.
The approval also changes the drug’s regulatory status from investigational access to an authorized use for the population on the label. In May, the FDA issued a safe-to-proceed letter that allowed Revolution Medicines to begin an expanded-access treatment protocol before the decision. Expanded access can provide a route to an investigational product outside a clinical trial for qualifying patients; it is not the same as an FDA finding that a drug is safe and effective for marketing.
The agency said Rasonque received Breakthrough Therapy and Orphan Drug designations and was reviewed under Priority Review. Its application also went through the Commissioner’s National Priority Voucher pilot program, with the FDA saying approval arrived 6.5 months before the agency’s user-fee deadline.
Cost and insurance coverage may shape how readily patients can use the drug. USA Today reported that the listed price is $39,800 for a 30-day supply, citing Revolution Medicines and Reuters, and that eligible commercially insured patients may qualify for copay assistance. Those commercial terms are separate from the FDA’s assessment of the medicine.
For oncologists and patients confronting metastatic pancreatic adenocarcinoma after prior treatment, Rasonque now offers a new labeled option supported by a randomized survival comparison. How its benefits and harms translate across patients who were not represented in the trial, including those with different treatment histories or earlier disease, remains outside the evidence underlying this approval.